Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 3

JCO Precision Oncology

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers -

PURPOSE To examine the overlap of homologous recombination deficiency (HRD) and microsatellite instability high (MSI-H) status, and to dissect driver versus bystander status of

1542912721015824384

Toni Choueiri, MD

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers | in ⁦@JCO_ASCO⁩ Precision Oncology MSI-H #ProstateCancer with BRCAm do not benefit from PARPi…. ⁦@OncoAlert⁩ https://t.co/7O3DnkAN6n - view on twitter

More coverage: #ProstateCancer

Read the full article here

See more from Toni Choueiri, MD